Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Laboratory analysis of CDH1 missense mutation

Prof. Raquel Seruca - IPATIMUP-I3S, Porto, Portugal
Laboratory analysis of CDH1 missense mutation ( Prof. Raquel Seruca - IPATIMUP-I3S, Porto, Portugal )
22 Jul 2020

Why the ADAURA study is a big step forward for NSCLC

Dr Luis Raez - Memorial Cancer Institute, Florida, USA
Why the ADAURA study is a big step forward for NSCLC ( Dr Luis Raez - Memorial Cancer Institute, Florida, USA )
17 Jul 2020

CheckMate 459: Long-term survival outcomes with nivolumab versus sorafenib as first-line treatment in aHCC

Prof Bruno Sangro - University of Navarra, Pamplona, Spain
CheckMate 459: Long-term survival outcomes with nivolumab versus sorafenib as first-line treatment in aHCC ( Prof Bruno Sangro - University of Navarra, Pamplona, Spain )
15 Jul 2020

Novel immunotherapy approaches for small cell lung cancer

Dr Triparna Sen - Memorial Sloan Kettering Cancer Center, New York City, USA
Novel immunotherapy approaches for small cell lung cancer ( Dr Triparna Sen - Memorial Sloan Kettering Cancer Center, New York City, USA )
15 Jul 2020

Renal cell cancer: Highlights from ASCO 2020

Prof Scott Tykodi - University of Washington, Seattle, USA
Renal cell cancer: Highlights from ASCO 2020 ( Prof Scott Tykodi - University of Washington, Seattle, USA )
13 Jul 2020

HERO: Relugolix versus leuprolide acetate for advanced prostate cancer

Dr Neal Shore - Carolina Urologic Research Center, South Carolina, USA
HERO: Relugolix versus leuprolide acetate for advanced prostate cancer ( Dr Neal Shore - Carolina Urologic Research Center, South Carolina, USA )
10 Jul 2020

MASTER trial updates: Dara-KRd induction, autologous transplantation and MRD response-adapted consolidation in NDMM

Dr Luciano Costa - O'Neal Comprehensive Cancer Center at UAB, Birmingham, USA
MASTER trial updates: Dara-KRd induction, autologous transplantation and MRD response-adapted consolidation in NDMM ( Dr Luciano Costa - O'Neal Comprehensive Cancer Center at UAB, Birmingham, USA )
9 Jul 2020

UKALL2011: Treatment with a tyrosine kinase inhibitor improves outcomes for patients with acute lymphoblastic leukaemia and an ABL-class fusion

Prof Anthony Moorman - Newcastle University, Newcastle upon Tyne, UK
UKALL2011: Treatment with a tyrosine kinase inhibitor improves outcomes for patients with acute lymphoblastic leukaemia and an ABL-class fusion ( Prof Anthony Moorman - Newcastle University, Newcastle upon Tyne, UK )
9 Jul 2020

Phase I/II results: First-line NALIRIFOX in patients with pancreatic ductal adenocarcinoma

Dr Zev Wainberg - Ronald Reagan UCLA Medical Center, Los Angeles, USA
Phase I/II results: First-line NALIRIFOX in patients with pancreatic ductal adenocarcinoma ( Dr Zev Wainberg - Ronald Reagan UCLA Medical Center, Los Angeles, USA )
8 Jul 2020

Long-term disease control in multiple myeloma by in-class transitioning: A community-based study

Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA
Long-term disease control in multiple myeloma by in-class transitioning: A community-based study ( Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA )
3 Jul 2020

Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma

Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA
Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma ( Dr Elias Jabbour -  MD Anderson Cancer Center, Houston, USA )
3 Jul 2020

The future of PARP inhibitors in prostate cancer

Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain
The future of PARP inhibitors in prostate cancer ( Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain )
2 Jul 2020